66248-1-Ig
antibody from Proteintech Group
Targeting: CD274
B7-H, B7-H1, B7H1, PD-L1, PDCD1LG1, PDL1
Antibody data
- Antibody Data
- Antigen structure
- References [90]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 66248-1-Ig - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#66248-1-Ig, RRID:AB_2756526
- Product name
- PD-L1/CD274 antibody
- Antibody type
- Monoclonal
- Description
- KD/KO validated PD-L1/CD274 antibody (Cat. #66248-1-Ig) is a mouse monoclonal antibody that shows reactivity with human, mouse, pig, rat and has been validated for the following applications: FC, IF, IHC, WB, ELISA.
- Reactivity
- Human, Mouse, Rat, Porcine
- Host
- Mouse
- Conjugate
- Unconjugated
- Isotype
- IgG
- Antibody clone number
- 2B11D11
- Vial size
- 20ul, 150ul
Submitted references The immunomodulatory effect of microglia on ECM neuroinflammation via the PD-1/PD-L1 pathway.
A miR-129-5P/ARID3A Negative Feedback Loop Modulates Diffuse Large B Cell Lymphoma Progression and Immune Evasion Through Regulating the PD-1/PD-L1 Checkpoint.
ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
The Landscape of Immune Cells Indicates Prognosis and Applicability of Checkpoint Therapy in Hepatocellular Carcinoma.
CXCL10 Produced by HPV-Positive Cervical Cancer Cells Stimulates Exosomal PDL1 Expression by Fibroblasts via CXCR3 and JAK-STAT Pathways.
Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy.
PD-L1 evaluation in head and neck squamous cell carcinoma: Insights regarding specimens, heterogeneity and therapy.
Gut-derived lipopolysaccharide remodels tumoral microenvironment and synergizes with PD-L1 checkpoint blockade via TLR4/MyD88/AKT/NF-κB pathway in pancreatic cancer.
The PD-1/PD-L1 pathway in murine hair cycle transition: a potential anagen phase regulator.
Inhibition of PAI-1 Blocks PD-L1 Endocytosis and Improves the Response of Melanoma Cells to Immune Checkpoint Blockade.
Cisplatin nanoparticles possess stronger anti-tumor synergy with PD1/PD-L1 inhibitors than the parental drug.
Histopathologic PD-L1 Tumor Expression and Prognostic Significance in Nonmelanoma Skin Cancers: A Systematic Review.
STAT3/NF-κB signalling disruption in M2 tumour-associated macrophages is a major target of PLGA nanocarriers/PD-L1 antibody immunomodulatory therapy in breast cancer.
Tumor cell membrane-based peptide delivery system targeting the tumor microenvironment for cancer immunotherapy and diagnosis.
WSX1 act as a tumor suppressor in hepatocellular carcinoma by downregulating neoplastic PD-L1 expression.
Cisplatin remodels the tumor immune microenvironment via the transcription factor EB in ovarian cancer.
Identification of vitamin B6 as a PD-L1 suppressor and an adjuvant for cancer immunotherapy.
NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1.
Relationship between PD-L1 expression, CD8+ T-cell infiltration and prognosis in intrahepatic cholangiocarcinoma patients.
The association of CMTM6 expression with prognosis and PD-L1 expression in triple-negative breast cancer.
Nutritional supplements in combination with chemotherapy or targeted therapy reduces tumor progression in mice bearing triple-negative breast cancer.
NAD+ Metabolism Maintains Inducible PD-L1 Expression to Drive Tumor Immune Evasion.
NLRP3 inflammasome upregulates PD-L1 expression and contributes to immune suppression in lymphoma.
Prostate cancer C5a receptor expression and augmentation of cancer cell proliferation, invasion, and PD-L1 expression by C5a.
Immune subtyping for pancreatic cancer with implication in clinical outcomes and improving immunotherapy.
Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid membrane-coated nanoparticles.
The impact of tobacco exposure on tumor microenvironment and prognosis in lung adenocarcinoma by integrative analysis of multi-omics data.
Cascade-Responsive Hierarchical Nanosystems for Multisite Specific Drug Exposure and Boosted Chemoimmunotherapy.
OSCC cell-secreted exosomal CMTM6 induced M2-like macrophages polarization via ERK1/2 signaling pathway.
ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation.
Amplification and expression of c-MET correlate with poor prognosis of patients with gastric cancer and upregulate the expression of PDL1.
PD-L1 lncRNA splice isoform promotes lung adenocarcinoma progression via enhancing c-Myc activity.
p.P476S mutation of RBPJL inhibits the efficacy of anti-PD-1 therapy in oesophageal squamous cell carcinoma by blunting T-cell responses.
Nanobodies targeting the interaction interface of programmed death receptor 1 (PD-1)/PD-1 ligand 1 (PD-1/PD-L1).
BTLA Expression in Stage I-III Non-Small-Cell Lung Cancer and Its Correlation with PD-1/PD-L1 and Clinical Outcomes.
Role of GLUT-1 in the Upregulation of PD-L1 Expression After Radiotherapy and Association of PD-L1 with Favourable Overall Survival in Hypopharyngeal Cancer.
LncRNA EMX2OS Induces Proliferation, Invasion and Sphere Formation of Ovarian Cancer Cells via Regulating the miR-654-3p/AKT3/PD-L1 Axis.
Arsenic trioxide (ATO) induced degradation of Cyclin D1 sensitized PD-1/PD-L1 checkpoint inhibitor in oral and esophageal squamous cell carcinoma.
The stabilization of PD-L1 by the endoplasmic reticulum stress protein GRP78 in triple-negative breast cancer.
Prognostic and Clinicopathological Value of Programmed Cell Death Ligand1 Expression in Patients With Small Cell Lung Cancer: A Meta-Analysis.
PD-L1 Under Regulation of miR-429 Influences the Sensitivity of Gastric Cancer Cells to TRAIL by Binding of EGFR.
Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells.
Small-molecule MMP2/MMP9 inhibitor SB-3CT modulates tumor immune surveillance by regulating PD-L1.
Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice.
Mitosis in Cancer Cell Increases Immune Resistance via High Expression of HLA-G and PD-L1.
α-Cyperone inhibits the proliferation of human cervical cancer HeLa cells via ROS-mediated PI3K/Akt/mTOR signaling pathway.
Tumour PD-L1 Expression in Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Calcium Channel Blocker Nifedipine Suppresses Colorectal Cancer Progression and Immune Escape by Preventing NFAT2 Nuclear Translocation.
Synergistic anti-liver cancer effects of curcumin and total ginsenosides.
Novel gene-specific translation mechanism of dysregulated, chronic inflammation reveals promising, multifaceted COVID-19 therapeutics.
Clinical importance of VEGFC and PD-L1 co-expression in lung adenocarcinoma patients.
ROS1-fusion protein induces PD-L1 expression via MEK-ERK activation in non-small cell lung cancer.
anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells.
NME4 modulates PD-L1 expression via the STAT3 signaling pathway in squamous cell carcinoma.
Programmed Cell Death-1: Programmed Cell Death-Ligand 1 Interaction Protects Human Cardiomyocytes Against T-Cell Mediated Inflammation and Apoptosis Response In Vitro.
ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis.
Angiotensin II contributes to intratumoral immunosuppressionvia induction of PD-L1 expression in non-small cell lung carcinoma.
Developing Covalent Protein Drugs via Proximity-Enabled Reactive Therapeutics.
Ginsenoside Rk1 induces apoptosis and downregulates the expression of PD-L1 by targeting the NF-κB pathway in lung adenocarcinoma.
The role of myeloid-derived suppressor cells in increasing cancer stem-like cells and promoting PD-L1 expression in epithelial ovarian cancer.
An Analysis of Isoclonal Antibody Formats Suggests a Role for Measuring PD-L1 with Low Molecular Weight PET Radiotracers.
Analysis of Cyclooxygenase 2, Programmed Cell Death Ligand 1, and Arginase 1 Expression in Human Pituitary Adenoma.
PD-L1 as a prognostic biomarker in surgically resectable non-small cell lung cancer: a meta-analysis.
Down Regulation of c-FLIPL Enhance PD-1 Blockade Efficacy in B16 Melanoma.
Prognostic Value of the Neo-Immunoscore in Renal Cell Carcinoma.
PD-L1 Expression Is Associated With VEGFA and LADC Patients' Survival.
Berberine Maintains the Neutrophil N1 Phenotype to Reverse Cancer Cell Resistance to Doxorubicin.
EZH2 regulates PD-L1 expression via HIF-1α in non-small cell lung cancer cells.
Reduced expression of PD-L1 in autoimmune thyroiditis attenuate trophoblast invasion through ERK/MMP pathway.
FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway.
Survival analysis with regard to PD-L1 and CD155 expression in human small cell lung cancer and a comparison with associated receptors.
Aberrant PD-1 ligand expression contributes to the myocardial inflammatory injury caused by Coxsackievirus B infection.
PD-L1 Expression and Tumor-Infiltrating Lymphocytes in High-Risk and Metastatic Cutaneous Squamous Cell Carcinoma.
CDK5 Regulates PD-L1 Expression and Cell Maturation in Dendritic Cells of CRSwNP.
MLL3 enhances the transcription of PD-L1 and regulates anti-tumor immunity.
Elevated serum soluble programmed cell death ligand 1 concentration as a potential marker for poor prognosis in small cell lung cancer patients with chemotherapy.
STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion.
Tristetraprolin Overexpression in Gastric Cancer Cells Suppresses PD-L1 Expression and Inhibits Tumor Progression by Enhancing Antitumor Immunity.
MiR-142 inhibits cecal ligation and puncture (CLP)-induced inflammation via inhibiting PD-L1 expression in macrophages and improves survival in septic mice.
A case of metastatic basal cell carcinoma treated with continuous PD-1 inhibitor exposure even after subsequent initiation of radiotherapy and surgery.
Association of PD-L1 and HIF-1α Coexpression with Poor Prognosis in Hepatocellular Carcinoma.
Programmed death-1 ligands 1 and 2 expression in cutaneous squamous cell carcinoma and their relationship with tumour- infiltrating dendritic cells.
Positive Expression of Programmed Death Ligand 1 in Peritumoral Liver Tissue is Associated with Poor Survival after Curative Resection of Hepatocellular Carcinoma.
Association Between Programmed Death Ligand 1 Expression in Patients With Basal Cell Carcinomas and the Number of Treatment Modalities.
Altered expression of programmed death-ligand 1 after neo-adjuvant chemotherapy in patients with lung squamous cell carcinoma.
Efficacy of short-term nivolumab treatment in a Chinese patient with relapsed advanced-stage lung squamous cell carcinoma: A case report.
Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma.
Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma.
PD-L1 Expression in Lung Cancer.
PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy.
Shen Y, Li Y, Zhu Q, Wang J, Huang Y, Liang J, Wu X, Zhao Y
CNS neuroscience & therapeutics 2022 Jan;28(1):46-63
CNS neuroscience & therapeutics 2022 Jan;28(1):46-63
A miR-129-5P/ARID3A Negative Feedback Loop Modulates Diffuse Large B Cell Lymphoma Progression and Immune Evasion Through Regulating the PD-1/PD-L1 Checkpoint.
Zheng W, Lai G, Lin Q, Issah MA, Fu H, Shen J
Frontiers in cell and developmental biology 2021;9:735855
Frontiers in cell and developmental biology 2021;9:735855
ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X, Gao A, Zhang F, Yang Z, Wang S, Fang Y, Li J, Wang J, Shi W, Wang L, Zheng Y, Sun Y
Theranostics 2021;11(7):3392-3416
Theranostics 2021;11(7):3392-3416
The Landscape of Immune Cells Indicates Prognosis and Applicability of Checkpoint Therapy in Hepatocellular Carcinoma.
Huang J, Zhang L, Chen J, Wan D, Zhou L, Zheng S, Qiao Y
Frontiers in oncology 2021;11:744951
Frontiers in oncology 2021;11:744951
CXCL10 Produced by HPV-Positive Cervical Cancer Cells Stimulates Exosomal PDL1 Expression by Fibroblasts via CXCR3 and JAK-STAT Pathways.
Chen X, He H, Xiao Y, Hasim A, Yuan J, Ye M, Li X, Hao Y, Guo X
Frontiers in oncology 2021;11:629350
Frontiers in oncology 2021;11:629350
Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy.
Li E, Huang X, Zhang G, Liang T
Journal of experimental & clinical cancer research : CR 2021 Sep 3;40(1):279
Journal of experimental & clinical cancer research : CR 2021 Sep 3;40(1):279
PD-L1 evaluation in head and neck squamous cell carcinoma: Insights regarding specimens, heterogeneity and therapy.
Paolino G, Pantanowitz L, Barresi V, Pagni F, Munari E, Moretta L, Brunelli M, Bariani E, Vigliar E, Pisapia P, Malapelle U, Troncone G, Girolami I, Eccher A
Pathology, research and practice 2021 Oct;226:153605
Pathology, research and practice 2021 Oct;226:153605
Gut-derived lipopolysaccharide remodels tumoral microenvironment and synergizes with PD-L1 checkpoint blockade via TLR4/MyD88/AKT/NF-κB pathway in pancreatic cancer.
Yin H, Pu N, Chen Q, Zhang J, Zhao G, Xu X, Wang D, Kuang T, Jin D, Lou W, Wu W
Cell death & disease 2021 Oct 30;12(11):1033
Cell death & disease 2021 Oct 30;12(11):1033
The PD-1/PD-L1 pathway in murine hair cycle transition: a potential anagen phase regulator.
Zhou L, Wen L, Sheng Y, Lu J, Hu R, Wang X, Lu Z, Yang Q
Archives of dermatological research 2021 Nov;313(9):751-758
Archives of dermatological research 2021 Nov;313(9):751-758
Inhibition of PAI-1 Blocks PD-L1 Endocytosis and Improves the Response of Melanoma Cells to Immune Checkpoint Blockade.
Tseng YJ, Lee CH, Chen WY, Yang JL, Tzeng HT
The Journal of investigative dermatology 2021 Nov;141(11):2690-2698.e6
The Journal of investigative dermatology 2021 Nov;141(11):2690-2698.e6
Cisplatin nanoparticles possess stronger anti-tumor synergy with PD1/PD-L1 inhibitors than the parental drug.
Shen N, Yang C, Zhang X, Tang Z, Chen X
Acta biomaterialia 2021 Nov;135:543-555
Acta biomaterialia 2021 Nov;135:543-555
Histopathologic PD-L1 Tumor Expression and Prognostic Significance in Nonmelanoma Skin Cancers: A Systematic Review.
Lehmer L, Choi F, Kraus C, Shiu J, de Feraudy S, Elsensohn A
The American Journal of dermatopathology 2021 May 1;43(5):321-330
The American Journal of dermatopathology 2021 May 1;43(5):321-330
STAT3/NF-κB signalling disruption in M2 tumour-associated macrophages is a major target of PLGA nanocarriers/PD-L1 antibody immunomodulatory therapy in breast cancer.
Cavalcante RS, Ishikawa U, Silva ES, Silva-Júnior AA, Araújo AA, Cruz LJ, Chan AB, de Araújo Júnior RF
British journal of pharmacology 2021 Jun;178(11):2284-2304
British journal of pharmacology 2021 Jun;178(11):2284-2304
Tumor cell membrane-based peptide delivery system targeting the tumor microenvironment for cancer immunotherapy and diagnosis.
Meng X, Wang J, Zhou J, Tian Q, Qie B, Zhou G, Duan W, Zhu Y
Acta biomaterialia 2021 Jun;127:266-275
Acta biomaterialia 2021 Jun;127:266-275
WSX1 act as a tumor suppressor in hepatocellular carcinoma by downregulating neoplastic PD-L1 expression.
Wu M, Xia X, Hu J, Fowlkes NW, Li S
Nature communications 2021 Jun 9;12(1):3500
Nature communications 2021 Jun 9;12(1):3500
Cisplatin remodels the tumor immune microenvironment via the transcription factor EB in ovarian cancer.
Liu W, Wang Y, Xie Y, Dai T, Fan M, Li C, Zou Y
Cell death discovery 2021 Jun 5;7(1):136
Cell death discovery 2021 Jun 5;7(1):136
Identification of vitamin B6 as a PD-L1 suppressor and an adjuvant for cancer immunotherapy.
Yuan J, Li J, Shang M, Fu Y, Wang T
Biochemical and biophysical research communications 2021 Jul 5;561:187-194
Biochemical and biophysical research communications 2021 Jul 5;561:187-194
NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1.
Zhang X, Huang X, Xu J, Li E, Lao M, Tang T, Zhang G, Guo C, Zhang X, Chen W, Yadav DK, Bai X, Liang T
Nature communications 2021 Jul 27;12(1):4536
Nature communications 2021 Jul 27;12(1):4536
Relationship between PD-L1 expression, CD8+ T-cell infiltration and prognosis in intrahepatic cholangiocarcinoma patients.
Deng M, Li SH, Fu X, Yan XP, Chen J, Qiu YD, Guo RP
Cancer cell international 2021 Jul 12;21(1):371
Cancer cell international 2021 Jul 12;21(1):371
The association of CMTM6 expression with prognosis and PD-L1 expression in triple-negative breast cancer.
Tian Y, Sun X, Cheng G, Ji E, Yang S, Feng J, Zheng L
Annals of translational medicine 2021 Jan;9(2):131
Annals of translational medicine 2021 Jan;9(2):131
Nutritional supplements in combination with chemotherapy or targeted therapy reduces tumor progression in mice bearing triple-negative breast cancer.
Guo CH, Hsia S, Chung CH, Lin YC, Shih MY, Chen PC, Peng CL, Henning SM, Hsu GW, Li Z
The Journal of nutritional biochemistry 2021 Jan;87:108504
The Journal of nutritional biochemistry 2021 Jan;87:108504
NAD+ Metabolism Maintains Inducible PD-L1 Expression to Drive Tumor Immune Evasion.
Lv H, Lv G, Chen C, Zong Q, Jiang G, Ye D, Cui X, He Y, Xiang W, Han Q, Tang L, Yang W, Wang H
Cell metabolism 2021 Jan 5;33(1):110-127.e5
Cell metabolism 2021 Jan 5;33(1):110-127.e5
NLRP3 inflammasome upregulates PD-L1 expression and contributes to immune suppression in lymphoma.
Lu F, Zhao Y, Pang Y, Ji M, Sun Y, Wang H, Zou J, Wang Y, Li G, Sun T, Li J, Ma D, Ye J, Ji C
Cancer letters 2021 Jan 28;497:178-189
Cancer letters 2021 Jan 28;497:178-189
Prostate cancer C5a receptor expression and augmentation of cancer cell proliferation, invasion, and PD-L1 expression by C5a.
Imamura R, Kitagawa S, Kubo T, Irie A, Kariu T, Yoneda M, Kamba T, Imamura T
The Prostate 2021 Feb;81(3):147-156
The Prostate 2021 Feb;81(3):147-156
Immune subtyping for pancreatic cancer with implication in clinical outcomes and improving immunotherapy.
Liu J, Liu Q, Zhang X, Cui M, Li T, Zhang Y, Liao Q
Cancer cell international 2021 Feb 26;21(1):137
Cancer cell international 2021 Feb 26;21(1):137
Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid membrane-coated nanoparticles.
Gong C, Yu X, Zhang W, Han L, Wang R, Wang Y, Gao S, Yuan Y
Journal of nanobiotechnology 2021 Feb 25;19(1):58
Journal of nanobiotechnology 2021 Feb 25;19(1):58
The impact of tobacco exposure on tumor microenvironment and prognosis in lung adenocarcinoma by integrative analysis of multi-omics data.
Lu X, Ma L, Yin X, Ji H, Qian Y, Zhong S, Yan A, Zhang Y
International immunopharmacology 2021 Dec;101(Pt B):108253
International immunopharmacology 2021 Dec;101(Pt B):108253
Cascade-Responsive Hierarchical Nanosystems for Multisite Specific Drug Exposure and Boosted Chemoimmunotherapy.
Zhang J, Zhang Y, Zhao B, Lv M, Chen E, Zhao C, Jiang L, Qian H, Huang D, Zhong Y, Chen W
ACS applied materials & interfaces 2021 Dec 15;13(49):58319-58328
ACS applied materials & interfaces 2021 Dec 15;13(49):58319-58328
OSCC cell-secreted exosomal CMTM6 induced M2-like macrophages polarization via ERK1/2 signaling pathway.
Pang X, Wang SS, Zhang M, Jiang J, Fan HY, Wu JS, Wang HF, Liang XH, Tang YL
Cancer immunology, immunotherapy : CII 2021 Apr;70(4):1015-1029
Cancer immunology, immunotherapy : CII 2021 Apr;70(4):1015-1029
ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation.
Wu Y, Zhang C, Liu X, He Z, Shan B, Zeng Q, Zhao Q, Zhu H, Liao H, Cen X, Xu X, Zhang M, Hou T, Wang Z, Yan H, Yang S, Sun Y, Chen Y, Wu R, Xie T, Chen W, Najafov A, Ying S, Xia H
Nature communications 2021 Apr 20;12(1):2346
Nature communications 2021 Apr 20;12(1):2346
Amplification and expression of c-MET correlate with poor prognosis of patients with gastric cancer and upregulate the expression of PDL1.
Yang Y, Wang C, Dai C, Liu X, Li W, Huang M, Zhao X, Ji D, Li J, Guo W
Acta biochimica et biophysica Sinica 2021 Apr 15;53(5):547-557
Acta biochimica et biophysica Sinica 2021 Apr 15;53(5):547-557
PD-L1 lncRNA splice isoform promotes lung adenocarcinoma progression via enhancing c-Myc activity.
Qu S, Jiao Z, Lu G, Yao B, Wang T, Rong W, Xu J, Fan T, Sun X, Yang R, Wang J, Yao Y, Xu G, Yan X, Wang T, Liang H, Zen K
Genome biology 2021 Apr 13;22(1):104
Genome biology 2021 Apr 13;22(1):104
p.P476S mutation of RBPJL inhibits the efficacy of anti-PD-1 therapy in oesophageal squamous cell carcinoma by blunting T-cell responses.
Miao L, Wei XL, Zhao Q, Qi J, Ren C, Wu QN, Wei DL, Liu J, Wang FH, Xu RH
Clinical & translational immunology 2020;9(9):e1172
Clinical & translational immunology 2020;9(9):e1172
Nanobodies targeting the interaction interface of programmed death receptor 1 (PD-1)/PD-1 ligand 1 (PD-1/PD-L1).
Wen B, Zhao L, Wang Y, Qiu C, Xu Z, Huang K, Zhu H, Li Z, Li H
Preparative biochemistry & biotechnology 2020;50(3):252-259
Preparative biochemistry & biotechnology 2020;50(3):252-259
BTLA Expression in Stage I-III Non-Small-Cell Lung Cancer and Its Correlation with PD-1/PD-L1 and Clinical Outcomes.
Li X, Xu Z, Cui G, Yu L, Zhang X
OncoTargets and therapy 2020;13:215-224
OncoTargets and therapy 2020;13:215-224
Role of GLUT-1 in the Upregulation of PD-L1 Expression After Radiotherapy and Association of PD-L1 with Favourable Overall Survival in Hypopharyngeal Cancer.
Shen LF, Zhou SH, Guo Y
OncoTargets and therapy 2020;13:11221-11235
OncoTargets and therapy 2020;13:11221-11235
LncRNA EMX2OS Induces Proliferation, Invasion and Sphere Formation of Ovarian Cancer Cells via Regulating the miR-654-3p/AKT3/PD-L1 Axis.
Duan M, Fang M, Wang C, Wang H, Li M
Cancer management and research 2020;12:2141-2154
Cancer management and research 2020;12:2141-2154
Arsenic trioxide (ATO) induced degradation of Cyclin D1 sensitized PD-1/PD-L1 checkpoint inhibitor in oral and esophageal squamous cell carcinoma.
Zhu G, Li X, Li J, Zhou W, Chen Z, Fan Y, Jiang Y, Zhao Y, Sun G, Mao W
Journal of Cancer 2020;11(22):6516-6529
Journal of Cancer 2020;11(22):6516-6529
The stabilization of PD-L1 by the endoplasmic reticulum stress protein GRP78 in triple-negative breast cancer.
Chou CW, Yang RY, Chan LC, Li CF, Sun L, Lee HH, Lee PC, Sher YP, Ying H, Hung MC
American journal of cancer research 2020;10(8):2621-2634
American journal of cancer research 2020;10(8):2621-2634
Prognostic and Clinicopathological Value of Programmed Cell Death Ligand1 Expression in Patients With Small Cell Lung Cancer: A Meta-Analysis.
Cai H, Zhang H, Jiang Y
Frontiers in oncology 2020;10:1079
Frontiers in oncology 2020;10:1079
PD-L1 Under Regulation of miR-429 Influences the Sensitivity of Gastric Cancer Cells to TRAIL by Binding of EGFR.
Lv J, Guo T, Qu X, Che X, Li C, Wang S, Gong J, Wu P, Liu Y, Liu Y, Xu L
Frontiers in oncology 2020;10:1067
Frontiers in oncology 2020;10:1067
Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells.
Yan Y, Zheng L, Du Q, Yan B, Geller DA
Cancer immunology, immunotherapy : CII 2020 Sep;69(9):1891-1903
Cancer immunology, immunotherapy : CII 2020 Sep;69(9):1891-1903
Small-molecule MMP2/MMP9 inhibitor SB-3CT modulates tumor immune surveillance by regulating PD-L1.
Ye Y, Kuang X, Xie Z, Liang L, Zhang Z, Zhang Y, Ma F, Gao Q, Chang R, Lee HH, Zhao S, Su J, Li H, Peng J, Chen H, Yin M, Peng C, Yang N, Wang J, Liu J, Liu H, Han L, Chen X
Genome medicine 2020 Sep 28;12(1):83
Genome medicine 2020 Sep 28;12(1):83
Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice.
Qin W, Zou J, Huang Y, Liu C, Kang Y, Han H, Tang Y, Li L, Liu B, Zhao W, Yuan X
Oncoimmunology 2020 Sep 22;9(1):1824631
Oncoimmunology 2020 Sep 22;9(1):1824631
Mitosis in Cancer Cell Increases Immune Resistance via High Expression of HLA-G and PD-L1.
Ullah M, Aoudjeghout W, Pimpie C, Pocard M, Mirshahi M
Cancers 2020 Sep 18;12(9)
Cancers 2020 Sep 18;12(9)
α-Cyperone inhibits the proliferation of human cervical cancer HeLa cells via ROS-mediated PI3K/Akt/mTOR signaling pathway.
Pei XD, Yao HL, Shen LQ, Yang Y, Lu L, Xiao JS, Wang XY, He ZL, Jiang LH
European journal of pharmacology 2020 Sep 15;883:173355
European journal of pharmacology 2020 Sep 15;883:173355
Tumour PD-L1 Expression in Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Acheampong E, Abed A, Morici M, Bowyer S, Amanuel B, Lin W, Millward M, Gray ES
Cells 2020 Oct 31;9(11)
Cells 2020 Oct 31;9(11)
Calcium Channel Blocker Nifedipine Suppresses Colorectal Cancer Progression and Immune Escape by Preventing NFAT2 Nuclear Translocation.
Wu L, Lin W, Liao Q, Wang H, Lin C, Tang L, Lian W, Chen Z, Li K, Xu L, Zhou R, Ding Y, Zhao L
Cell reports 2020 Oct 27;33(4):108327
Cell reports 2020 Oct 27;33(4):108327
Synergistic anti-liver cancer effects of curcumin and total ginsenosides.
Deng Z, Xu XY, Yunita F, Zhou Q, Wu YR, Hu YX, Wang ZQ, Tian XF
World journal of gastrointestinal oncology 2020 Oct 15;12(10):1091-1103
World journal of gastrointestinal oncology 2020 Oct 15;12(10):1091-1103
Novel gene-specific translation mechanism of dysregulated, chronic inflammation reveals promising, multifaceted COVID-19 therapeutics.
Wang L, Muneer A, Xie L, Zhang F, Wu B, Mei L, Lenarcic EM, Feng EH, Song J, Xiong Y, Yu X, Wang C, Gheorghe C, Torralba K, Cook JG, Wan YY, Moorman NJ, Song H, Jin J, Chen X
bioRxiv : the preprint server for biology 2020 Nov 16;
bioRxiv : the preprint server for biology 2020 Nov 16;
Clinical importance of VEGFC and PD-L1 co-expression in lung adenocarcinoma patients.
Qin T, Xia J, Liu S, Wang J, Liu H, Zhang Y, Jia Y, Li K
Thoracic cancer 2020 May;11(5):1139-1148
Thoracic cancer 2020 May;11(5):1139-1148
ROS1-fusion protein induces PD-L1 expression via MEK-ERK activation in non-small cell lung cancer.
Liu Z, Zhao K, Wei S, Liu C, Zhou J, Gou Q, Wu X, Yang Z, Yang Y, Peng Y, Cheng Q, Liu L
Oncoimmunology 2020 May 6;9(1):1758003
Oncoimmunology 2020 May 6;9(1):1758003
anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells.
Liu S, Qin T, Liu Z, Wang J, Jia Y, Feng Y, Gao Y, Li K
Cell death & disease 2020 May 4;11(5):309
Cell death & disease 2020 May 4;11(5):309
NME4 modulates PD-L1 expression via the STAT3 signaling pathway in squamous cell carcinoma.
Zheng S, Liu Q, Liu T, Yang L, Zhang Q, Shen T, Zhang X, Han X, Lu X
Biochemical and biophysical research communications 2020 May 21;526(1):29-34
Biochemical and biophysical research communications 2020 May 21;526(1):29-34
Programmed Cell Death-1: Programmed Cell Death-Ligand 1 Interaction Protects Human Cardiomyocytes Against T-Cell Mediated Inflammation and Apoptosis Response In Vitro.
Tay WT, Fang YH, Beh ST, Liu YW, Hsu LW, Yen CJ, Liu PY
International journal of molecular sciences 2020 Mar 31;21(7)
International journal of molecular sciences 2020 Mar 31;21(7)
ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis.
Liu H, Kuang X, Zhang Y, Ye Y, Li J, Liang L, Xie Z, Weng L, Guo J, Li H, Ma F, Chen X, Zhao S, Su J, Yang N, Fang F, Xie Y, Tao J, Zhang J, Chen M, Peng C, Sun L, Zhang X, Liu J, Han L, Xu X, Hung MC, Chen X
Cancer cell 2020 Mar 16;37(3):324-339.e8
Cancer cell 2020 Mar 16;37(3):324-339.e8
Angiotensin II contributes to intratumoral immunosuppressionvia induction of PD-L1 expression in non-small cell lung carcinoma.
Yang K, Zhou J, Chen Y, Chen Y, Chen L, Zhang P, Ma L, Jiang Z, Bian J, Yin W
International immunopharmacology 2020 Jul;84:106507
International immunopharmacology 2020 Jul;84:106507
Developing Covalent Protein Drugs via Proximity-Enabled Reactive Therapeutics.
Li Q, Chen Q, Klauser PC, Li M, Zheng F, Wang N, Li X, Zhang Q, Fu X, Wang Q, Xu Y, Wang L
Cell 2020 Jul 9;182(1):85-97.e16
Cell 2020 Jul 9;182(1):85-97.e16
Ginsenoside Rk1 induces apoptosis and downregulates the expression of PD-L1 by targeting the NF-κB pathway in lung adenocarcinoma.
Hu M, Yang J, Qu L, Deng X, Duan Z, Fu R, Liang L, Fan D
Food & function 2020 Jan 29;11(1):456-471
Food & function 2020 Jan 29;11(1):456-471
The role of myeloid-derived suppressor cells in increasing cancer stem-like cells and promoting PD-L1 expression in epithelial ovarian cancer.
Komura N, Mabuchi S, Shimura K, Yokoi E, Kozasa K, Kuroda H, Takahashi R, Sasano T, Kawano M, Matsumoto Y, Kodama M, Hashimoto K, Sawada K, Kimura T
Cancer immunology, immunotherapy : CII 2020 Dec;69(12):2477-2499
Cancer immunology, immunotherapy : CII 2020 Dec;69(12):2477-2499
An Analysis of Isoclonal Antibody Formats Suggests a Role for Measuring PD-L1 with Low Molecular Weight PET Radiotracers.
Wei J, Wang YH, Lee CY, Truillet C, Oh DY, Xu Y, Ruggero D, Flavell RR, VanBrocklin HF, Seo Y, Craik CS, Fong L, Wang CI, Evans MJ
Molecular imaging and biology 2020 Dec;22(6):1553-1561
Molecular imaging and biology 2020 Dec;22(6):1553-1561
Analysis of Cyclooxygenase 2, Programmed Cell Death Ligand 1, and Arginase 1 Expression in Human Pituitary Adenoma.
Zhao G, Chen W, He J, Cui C, Zhao L, Zhao Y, Sun C, Nie D, Jin F, Kong L
World neurosurgery 2020 Dec;144:e660-e673
World neurosurgery 2020 Dec;144:e660-e673
PD-L1 as a prognostic biomarker in surgically resectable non-small cell lung cancer: a meta-analysis.
Tuminello S, Sikavi D, Veluswamy R, Gamarra C, Lieberman-Cribbin W, Flores R, Taioli E
Translational lung cancer research 2020 Aug;9(4):1343-1360
Translational lung cancer research 2020 Aug;9(4):1343-1360
Down Regulation of c-FLIPL Enhance PD-1 Blockade Efficacy in B16 Melanoma.
Wang Y, Li JJ, Ba HJ, Wang KF, Wen XZ, Li DD, Zhu XF, Zhang XS
Frontiers in oncology 2019;9:857
Frontiers in oncology 2019;9:857
Prognostic Value of the Neo-Immunoscore in Renal Cell Carcinoma.
Guo C, Zhao H, Wang Y, Bai S, Yang Z, Wei F, Ren X
Frontiers in oncology 2019;9:439
Frontiers in oncology 2019;9:439
PD-L1 Expression Is Associated With VEGFA and LADC Patients' Survival.
Liu S, Qin T, Jia Y, Li K
Frontiers in oncology 2019;9:189
Frontiers in oncology 2019;9:189
Berberine Maintains the Neutrophil N1 Phenotype to Reverse Cancer Cell Resistance to Doxorubicin.
Zhang S, Zhou L, Zhang M, Wang Y, Wang M, Du J, Gu W, Kui F, Li J, Geng S, Du G
Frontiers in pharmacology 2019;10:1658
Frontiers in pharmacology 2019;10:1658
EZH2 regulates PD-L1 expression via HIF-1α in non-small cell lung cancer cells.
Zhao Y, Wang XX, Wu W, Long H, Huang J, Wang Z, Li T, Tang S, Zhu B, Chen D
Biochemical and biophysical research communications 2019 Sep 17;517(2):201-209
Biochemical and biophysical research communications 2019 Sep 17;517(2):201-209
Reduced expression of PD-L1 in autoimmune thyroiditis attenuate trophoblast invasion through ERK/MMP pathway.
Chen M, Gilbert N, Liu H
Reproductive biology and endocrinology : RB&E 2019 Oct 27;17(1):86
Reproductive biology and endocrinology : RB&E 2019 Oct 27;17(1):86
FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway.
Li P, Huang T, Zou Q, Liu D, Wang Y, Tan X, Wei Y, Qiu H
Journal of immunology (Baltimore, Md. : 1950) 2019 May 15;202(10):3065-3075
Journal of immunology (Baltimore, Md. : 1950) 2019 May 15;202(10):3065-3075
Survival analysis with regard to PD-L1 and CD155 expression in human small cell lung cancer and a comparison with associated receptors.
Xu Y, Cui G, Jiang Z, Li N, Zhang X
Oncology letters 2019 Mar;17(3):2960-2968
Oncology letters 2019 Mar;17(3):2960-2968
Aberrant PD-1 ligand expression contributes to the myocardial inflammatory injury caused by Coxsackievirus B infection.
Wang T, Chen S, Wang X, Huang Y, Qiu J, Fei Y, Chaulagain A, Chen Y, Wang Y, Lin L, Yan B, Wang Y, Wang W, Zhao W, Zhong Z
Antiviral research 2019 Jun;166:1-10
Antiviral research 2019 Jun;166:1-10
PD-L1 Expression and Tumor-Infiltrating Lymphocytes in High-Risk and Metastatic Cutaneous Squamous Cell Carcinoma.
Amoils M, Kim J, Lee C, Sunwoo JB, Colevas AD, Aasi SZ, Hollmig ST, Ma Y, Divi V
Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 2019 Jan;160(1):93-99
Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 2019 Jan;160(1):93-99
CDK5 Regulates PD-L1 Expression and Cell Maturation in Dendritic Cells of CRSwNP.
Liu CC, Zhang HL, Zhi LL, Jin P, Zhao L, Li T, Zhou XM, Sun DS, Cheng GH, Xin Q, Shi L, Xia M
Inflammation 2019 Feb;42(1):135-144
Inflammation 2019 Feb;42(1):135-144
MLL3 enhances the transcription of PD-L1 and regulates anti-tumor immunity.
Xiong W, Deng H, Huang C, Zen C, Jian C, Ye K, Zhong Z, Zhao X, Zhu L
Biochimica et biophysica acta. Molecular basis of disease 2019 Feb 1;1865(2):454-463
Biochimica et biophysica acta. Molecular basis of disease 2019 Feb 1;1865(2):454-463
Elevated serum soluble programmed cell death ligand 1 concentration as a potential marker for poor prognosis in small cell lung cancer patients with chemotherapy.
Jin J, Si J, Liu Y, Wang H, Ni R, Wang J
Respiratory research 2018 Oct 5;19(1):197
Respiratory research 2018 Oct 5;19(1):197
STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion.
Hsu JM, Xia W, Hsu YH, Chan LC, Yu WH, Cha JH, Chen CT, Liao HW, Kuo CW, Khoo KH, Hsu JL, Li CW, Lim SO, Chang SS, Chen YC, Ren GX, Hung MC
Nature communications 2018 May 15;9(1):1908
Nature communications 2018 May 15;9(1):1908
Tristetraprolin Overexpression in Gastric Cancer Cells Suppresses PD-L1 Expression and Inhibits Tumor Progression by Enhancing Antitumor Immunity.
Guo J, Qu H, Shan T, Chen Y, Chen Y, Xia J
Molecules and cells 2018 Jul 31;41(7):653-664
Molecules and cells 2018 Jul 31;41(7):653-664
MiR-142 inhibits cecal ligation and puncture (CLP)-induced inflammation via inhibiting PD-L1 expression in macrophages and improves survival in septic mice.
Zhen J, Chen W
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2018 Jan;97:1479-1485
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2018 Jan;97:1479-1485
A case of metastatic basal cell carcinoma treated with continuous PD-1 inhibitor exposure even after subsequent initiation of radiotherapy and surgery.
Cannon JGD, Russell JS, Kim J, Chang ALS
JAAD case reports 2018 Apr;4(3):248-250
JAAD case reports 2018 Apr;4(3):248-250
Association of PD-L1 and HIF-1α Coexpression with Poor Prognosis in Hepatocellular Carcinoma.
Dai X, Pi G, Yang SL, Chen GG, Liu LP, Dong HH
Translational oncology 2018 Apr;11(2):559-566
Translational oncology 2018 Apr;11(2):559-566
Programmed death-1 ligands 1 and 2 expression in cutaneous squamous cell carcinoma and their relationship with tumour- infiltrating dendritic cells.
Jiao Q, Liu C, Li W, Li W, Fang F, Qian Q, Zhang X
Clinical and experimental immunology 2017 Jun;188(3):420-429
Clinical and experimental immunology 2017 Jun;188(3):420-429
Positive Expression of Programmed Death Ligand 1 in Peritumoral Liver Tissue is Associated with Poor Survival after Curative Resection of Hepatocellular Carcinoma.
Dai X, Xue J, Hu J, Yang SL, Chen GG, Lai PBS, Yu C, Zeng C, Fang X, Pan X, Zhang T
Translational oncology 2017 Aug;10(4):511-517
Translational oncology 2017 Aug;10(4):511-517
Association Between Programmed Death Ligand 1 Expression in Patients With Basal Cell Carcinomas and the Number of Treatment Modalities.
Chang J, Zhu GA, Cheung C, Li S, Kim J, Chang AL
JAMA dermatology 2017 Apr 1;153(4):285-290
JAMA dermatology 2017 Apr 1;153(4):285-290
Altered expression of programmed death-ligand 1 after neo-adjuvant chemotherapy in patients with lung squamous cell carcinoma.
Song Z, Yu X, Zhang Y
Lung cancer (Amsterdam, Netherlands) 2016 Sep;99:166-71
Lung cancer (Amsterdam, Netherlands) 2016 Sep;99:166-71
Efficacy of short-term nivolumab treatment in a Chinese patient with relapsed advanced-stage lung squamous cell carcinoma: A case report.
Pi G, He H, Bi J, Li Y, Li Y, Zhang Y, Wang M, Han G, Lin C
Medicine 2016 Oct;95(40):e5077
Medicine 2016 Oct;95(40):e5077
Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma.
Takada K, Okamoto T, Shoji F, Shimokawa M, Akamine T, Takamori S, Katsura M, Suzuki Y, Fujishita T, Toyokawa G, Morodomi Y, Okano S, Oda Y, Maehara Y
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 Nov;11(11):1879-1890
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 Nov;11(11):1879-1890
Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma.
Song Z, Yu X, Cheng G, Zhang Y
Journal of translational medicine 2016 Jun 24;14(1):188
Journal of translational medicine 2016 Jun 24;14(1):188
PD-L1 Expression in Lung Cancer.
Yu H, Boyle TA, Zhou C, Rimm DL, Hirsch FR
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 Jul;11(7):964-75
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 Jul;11(7):964-75
PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy.
Chang YL, Yang CY, Lin MW, Wu CT, Yang PC
Lung cancer (Amsterdam, Netherlands) 2015 Jun;88(3):254-9
Lung cancer (Amsterdam, Netherlands) 2015 Jun;88(3):254-9
No comments: Submit comment
No validations: Submit validation data